Sepsis | Landscape & Forecast | Disease Landscape & Forecast

Publish date: July 2017

Login to access report


Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. It is one of the leading causes of death among developed countries, with over 10% mortality rates in sepsis patients and over 40% in patients who develop septic shock. To manage sepsis, immediate interventions are required, which include infection control, hemodynamic restoration with fluid resuscitation and vasopressors, and other supportive care approaches. With the last FDA-approved drug for severe sepsis (Eli Lilly’s Xigris) withdrawn in 2011 due to its failure to show survival benefits, all current therapies for sepsis are either used off-label and/or are generically available. Therefore, opportunity exists for drug developers who can address key areas of unmet need. However, given the field’s limited understanding of sepsis pathophysiology, developers will likely face challenges during clinical development of their novel agents.


  • How large are the U.S. and EU5 sepsis patient populations, and how will their size change through 2026? What percentage of these patients progress to septic shock?
  • How are sepsis patients diagnosed and managed? What are the key current therapies prescribed for the treatment of sepsis and what drives their use?
  • How have the updated definitions for sepsis impacted diagnosis and treatment of sepsis and septic shock?
  • What are the key areas of unmet need and to what extent will they be fulfilled by the therapies currently in the pipeline?
  • What challenges will developers encounter when conducting clinical trials for drugs to treat sepsis? What clinical and commercial impact will emerging drugs have on the sepsis market through 2026?​​​​​​


Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Update
      • Update February 2018
    • Executive Summary
      • Key Findings
    • Commercial Outlook
      • Key Findings
      • Drivers and Constraints
        • What Factors Are Driving Sales in Sepsis?
        • What Factors Are Constraining Sales in Sepsis?
      • Drug Class-Specific Trends
        • Novel Antibiotics in Sepsis Market
        • Novel Vasopressors in Sepsis Market
    • Forecast
    • Etiology and Pathophysiology
      • Key Findings
        • Disease Overview
      • Etiology
        • Etiology
      • Pathophysiology
        • Pathophysiology
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Events of Sepsis
        • Drug-Treated Diagnosed Events of Sepsis
        • Diagnosed Events by Severity
        • Diagnosed Events of Severe Sepsis by Pathogen
    • Current Treatment Overview
      • Key Findings
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
        • Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Antibiotics
        • Vasopressors
        • Anticoagulants
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Key Findings
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Sepsis
        • Future Attainment of Unmet Needs in Sepsis
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Sepsis
        • Antibiotics
        • Vasopressors
        • Anticoagulants
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Sepsis
      • Key Discontinuations and Failures in Sepsis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Sepsis Bibliography

Author(s): Jiamin Zhuo, PhD

Jiamin Zhuo, is a business insights analyst on the infectious, niche, and rare diseases team at Decision Resources Group. He provides expert insight into the commercial aspects of drug development and market dynamics in bacterial infections, including gram-negative infections and Methicillin-resistant Staphylococcus aureus . He attained his at the Mayo Graduate School, Mayo Clinic, in Minnesota and his in physiology from Peking University in China. Prior to joining DRG, Dr. Zhuo was a postdoctoral fellow at Boston University and MIT, where he gained extensive experience in quantitative research methods.